Literature DB >> 8857920

Paraoxonase genotypes, lipoprotein lipase activity, and HDL.

D N Nevin1, A Zambon, C E Furlong, R J Richter, R Humbert, J E Hokanson, J D Brunzell.   

Abstract

Paraxonase, an enzyme associated with the high density lipoprotein (HDL) particle, hydrolyzes paraoxon, the active metabolite of the insecticide parathion. Several studies have shown that paraxonase levels in humans have a distribution characteristic of two alleles, one with low activity and the other with high activity. Paraoxonase also has arylesterase activity, which does not exhibit activity polymorphism and can therefore serve as an estimate of enzyme protein. Although the ability of paraoxon to irreversibly inhibit lipoprotein lipase (LPL) has been exploited experimentally for many years, the role of plasma paraoxonase in lipoprotein metabolism is unknown. Seventy-two normal individuals were examined for paraoxonase genotypes, plasma paraoxonase and arylesterase activities, postheparin LPL and hepatic lipase (HL) activities, and lipoprotein levels to determine whether (1) paraoxonase activity or genotype determines lipoprotein levels via an effect on LPL or HL activity or (2) variation in LPL and HL activities determines HDL levels and indirectly affects paraoxonase activity and protein levels in plasma. In the entire group, paraoxonase activity was related to arylesterase activity and genotype. Whereas arylesterase activity was correlated with HDL cholesterol (HDL-C) and apolipoproteinA-I (apoA-I) levels, neither arylesterase nor paraoxonase was correlated with LPL or HL activity. Furthermore, LPL activity was positively correlated and HL inversely correlated with HDL cholesterol and apoA-I levels, whereas LPL was inversely correlated with triglyceride levels. The paraoxonase genotypes of the study group were 30 individuals homozygous for the low-activity allele, 38 heterozygotes, and 4 individuals homozygous for the high-activity allele. Paraoxonase genotype accounted for approximately .75 of the variation in paraoxonase activity. Paraoxonase activity was linearly related to arylesterase activity within each subgroup. No difference in either LPL or HL activity was seen as a function of paraoxonase genotype, nor were differences seen in plasma triglyceride or HDL-C by genotype by ANOVA. The relation between LPL and HL and components of HDL in the paraoxonase genotypic subgroups in general reflected the associations seen in the group as a whole. Multivariate analysis showed that LPL, HL, and arylesterase, a measure of paraoxonase mass, were independent predictors of HDL cholesterol, while paraoxonase genotype or activity was not. Thus, variation in LPL and HL appears to be significantly related to HDL cholesterol and apoA-I levels. The levels of HDL are a major correlate of paraoxonase protein levels, while paraoxonase genotype is the major predictor of plasma paraoxonase activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857920     DOI: 10.1161/01.atv.16.10.1243

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  16 in total

Review 1.  Dysfunctional high-density lipoprotein and atherosclerosis.

Authors:  Shawn Ragbir; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

2.  Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.

Authors:  György Paragh; Ildikó Seres; Mariann Harangi; Annamária Erdei; Mária Audikovszky; Lóránd Debreczeni; Anna Kovácsay; László Illyés; Gyula Pados
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

3.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Authors:  M Aviram; M Rosenblat; C L Bisgaier; R S Newton; S L Primo-Parmo; B N La Du
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 4.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

5.  A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions.

Authors:  Dajiang J Liu; Suzanne M Leal
Journal:  PLoS Genet       Date:  2010-10-14       Impact factor: 5.917

Review 6.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

7.  Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II).

Authors:  Marian C Cheung; Shalamar D Sibley; Jerry P Palmer; John F Oram; John D Brunzell
Journal:  J Lipid Res       Date:  2003-06-01       Impact factor: 5.922

8.  The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes.

Authors:  Mehryar Zargari; Fahimeh Sharafeddin; Abdolkarim Mahrooz; Ahad Alizadeh; Parisa Masoumi
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

9.  Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis.

Authors:  Nidhi Gupta; Surjit Singh; V Nagarjuna Maturu; Yash Paul Sharma; Kiran Dip Gill
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

10.  Paraoxonase gene polymorphisms and haplotype analysis in a stroke population.

Authors:  Alireza Pasdar; Helen Ross-Adams; Alastair Cumming; John Cheung; Lawrence Whalley; David St Clair; Mary-Joan MacLeod
Journal:  BMC Med Genet       Date:  2006-03-21       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.